Top Markets
Coin of the day
Arovella Therapeutics Limited Arovella Therapeutics Limited

Arovella Therapeutics Limited

ALA
주식 순위 #24896
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated... Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
주가
$0.04584351
시가총액
$55.42M
변동 (1일)
1.56%
변동 (1년)
-16.04%
국가
AU
거래 Arovella Therapeutics Limited (ALA)

카테고리

Arovella Therapeutics Limited (ALA)의 배당 수익률 기록
Arovella Therapeutics Limited (주식 심볼: ALA)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Arovella Therapeutics Limited (ALA)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
회사 배당 수익률 국가
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US